FindTrial
Sign In

Rocuronium evaluation for Maintenance and reversal in normal healthy patients and patients with mild systemic disease undergoing surgery lasting for one hour

Clinical Evaluation of Rocuronium in Indian Population for maintenance and reversal in ASA I & II patients.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2012/09/002952
Enrollment
180
Registered
2012-09-03
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- ASA grade I & II Patients undergoing surgery lasting for 1 hour

Interventions

Intervention1: Rocuronium: Rocuronium bolus dose 0.8 mg/kg. Method: Induction with fentanyl 2mcg/kg, 2ml of preservative free lignocaine i.v, (to abolish pain during the injection of propofol and roc

Sponsors

NIL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. ASA I & II Patients 2. Elective Surgeries lasting at least one hour or more. 3. Patients requiring neuro muscular blockade and endo tracheal intubation. 4. Adults below 60 years of Age

Exclusion criteria

Exclusion criteria: 1. ASA III and above 2. Patients with liver and kidney disease Intraoperative Patients temperature less than 33 degree centigrade 3. Caesarian section, Intestinal obstruction, electrolyte abnormalities Hypothyroidism, Cushingoid syndrome, treatment with aminoglycoside antibiotics. 4. History of allergic reaction to Rocuronium. 5. Requirement of Special tecnique- hypothermia, hypotension, circulatory arrest, cardiopulmonary bypass.

Design outcomes

Primary

MeasureTime frame
Time to Reversal in minsTimepoint: Duration of Extubation after administration of reversal in mins—

Secondary

MeasureTime frame
1.Movement to intubation 2.Movement during surgery 3.Total duration of surgery 4.Delayed recovery 5.Bolus dose at 0 hr 6.TOF 0 after bolus in mins 7.PTC 10 after in mins 8.Time of infusion started in mins after 0 hr 9.Time of infusion stopped in mins after 0 hr 10.Time of reversal given in mins after 0 hr 11.Time of Extubation in mins after 0 hrr 12.Duration after stopping infusion to get TOF 2/3 13.Duration of extubation after administrating reversal Timepoint: 1.Movement to intubation 2.Movement during surgery 3.Total duration of surgery 4.Delayed recovery 5.Bolus dose at 0 hr 6.TOF 0 after bolus in mins 7.PTC 10 after in mins 8.Time of infusion started in mins after 0 hr 9.Time of infusion stopped in mins after 0 hr 10.Time of reversal given in mins after 0 hr 11.Time of Extubation in mins after 0 hrr 12.Duration after stopping infusion to get TOF 2/3 13.Duration of extubation after administrating reversal—

Countries

India

Contacts

Public ContactDr Sunoor Jain

Max Super Speciality Hospital ( a unit of Balaji Medical & Diagnostic Research Centre )

arun.puri@maxhealthcare.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026